A multicenter, real-world study analysis: pembrolizumab changes treatment strategy for the patient with recurrent/metastatic head and neck squamous cell carcinoma.
Hu M, Li X, Feng H, Qiao Q, Hu G, Yang K, Song X, Cao Y, Kang M, Wang R, Liu R, Zhang Y, Huang L, Cao X, Liao W, Ma W, Sun X, Sun B, Liu X, Wu S, Li J, Sun Y, Zhu H, He T, Sun W, Hong X, Guo W, Zhou S, Meng Z, Hu Y, Shang W, Lin Q, Wu H, Gao J, Wu H, Han Y, Zhang S, Wang Y, Chen C, Lee NY, Yu J.
Hu M, et al. Among authors: li j.
Cancer Lett. 2025 Dec 1;634:217996. doi: 10.1016/j.canlet.2025.217996. Epub 2025 Aug 20.
Cancer Lett. 2025.
PMID: 40846296